Loading...
XHKG1093
Market cap7.17bUSD
Dec 23, Last price  
4.80HKD
1D
-0.21%
1Q
-7.34%
Jan 2017
11.37%
Name

CSPC Pharmaceutical Group Ltd

Chart & Performance

D1W1MN
XHKG:1093 chart
P/E
8.91
P/S
1.51
EPS
0.51
Div Yield, %
4.90%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
13.38%
Revenues
34.60b
-3.83%
2,610,915,5613,322,735,5303,548,310,2054,670,920,7666,013,841,0546,190,968,2006,625,558,4635,972,422,0723,338,688,8477,774,297,3698,760,121,5099,540,875,41911,075,281,93512,920,598,64218,468,727,83825,063,173,66528,027,389,22833,585,456,92535,975,851,17134,599,373,627
Net income
5.87b
-3.58%
260,628,214162,691,01715,404,486446,644,721828,167,274854,686,476640,608,155188,704,5811,741,017,093760,114,3071,014,300,5921,394,464,2121,881,106,5382,315,067,7863,210,005,6124,211,486,0015,159,655,0005,605,185,0006,091,390,0005,873,325,000
CFO
4.18b
-54.70%
534,651,673194,559,275231,441,311842,642,4961,335,102,7481,380,277,731858,228,069289,986,340401,049,058636,739,5401,444,513,4921,884,585,9282,611,265,9652,747,596,3923,889,186,2894,392,657,5067,674,414,4345,862,517,2769,225,191,8194,178,815,000
Dividend
Oct 31, 20240.16 HKD/sh
Earnings
May 26, 2025

Profile

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
URL
https://www.cspc.com.hk/
IPO date
Jun 21, 1994
Employees
25,587
Domiciled in
CN
Incorporated in
HK

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
34,599,374
-3.83%
35,975,851
7.12%
33,585,457
19.83%
Cost of revenue
25,869,874
26,240,450
23,703,451
Unusual Expense (Income)
NOPBT
8,729,499
9,735,401
9,882,006
NOPBT Margin
25.23%
27.06%
29.42%
Operating Taxes
1,316,679
1,570,131
1,396,806
Tax Rate
15.08%
16.13%
14.13%
NOPAT
7,412,820
8,165,270
8,485,200
Net income
5,873,325
-3.58%
6,091,390
8.67%
5,605,185
8.63%
Dividends
(2,726,253)
(2,438,510)
(2,037,726)
Dividend yield
3.16%
2.50%
2.01%
Proceeds from repurchase of equity
(200,358)
(177,805)
(474,593)
BB yield
0.23%
0.18%
0.47%
Debt
Debt current
599,843
331,831
47,003
Long-term debt
363,743
322,214
123,658
Deferred revenue
(55,620)
Other long-term liabilities
56,962
289,711
68,038
Net debt
(16,769,934)
(19,168,991)
(17,367,911)
Cash flow
Cash from operating activities
4,178,815
9,225,192
5,862,517
CAPEX
(1,786,276)
(3,166,159)
(2,119,301)
Cash from investing activities
607,267
(8,188,091)
(1,058,421)
Cash from financing activities
(2,300,981)
(2,222,971)
(2,646,700)
FCF
5,202,804
8,906,434
5,616,374
Balance
Cash
13,092,277
15,575,618
13,122,038
Long term investments
4,641,243
4,247,418
4,416,534
Excess cash
16,003,552
18,024,243
15,859,299
Stockholders' equity
40,096,771
35,619,576
32,922,764
Invested Capital
20,121,045
18,165,845
17,060,908
ROIC
38.72%
46.36%
54.84%
ROCE
23.79%
26.40%
29.60%
EV
Common stock shares outstanding
11,873,031
11,918,523
11,953,839
Price
7.26
-11.46%
8.20
-3.19%
8.47
7.35%
Market cap
86,198,205
-11.80%
97,731,889
-3.47%
101,249,016
7.34%
EV
71,071,705
80,184,517
84,910,555
EBITDA
9,846,989
10,951,554
10,923,009
EV/EBITDA
7.22
7.32
7.77
Interest
25,896
28,945
9,237
Interest/NOPBT
0.30%
0.30%
0.09%